Approved HCV Drugs
Approved HCV Drugs
AASLD 2016: Real-World Responses to HCV Treatment Among U.S. Veterans Match Best Clinical Trial Results
- Details
- Category: Approved HCV Drugs
- Published on Sunday, 13 November 2016 00:00
- Written by Keith Alcorn
Direct-acting antiviral treatment is curing people of hepatitis C in real-world clinical practice at similar rates to those seen in clinical trials, and there do not seem to be major differences between drug regimens, according to results of a large population study presented this weekend at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston.
AASLD 2016: Liver Cancer Risk Reduced After Hepatitis C Treatment, But Vigilance Needed
- Details
- Category: Approved HCV Drugs
- Published on Sunday, 13 November 2016 00:00
- Written by Keith Alcorn
People who are cured of hepatitis C after a course of direct-acting antiviral treatment do not have a higher risk of developing hepatocellular carcinoma (HCC) -- and probably have a reduced risk -- according to studies from Italy and Canada presented at American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston.
EASL Paris: AbbVie 3D Regimen for 8 Weeks Cures Almost All HCV Genotype 1b Patients
- Details
- Category: Approved HCV Drugs
- Published on Wednesday, 28 September 2016 00:00
- Written by Liz HIghleyman
AbbVie's paritaprevir-based 3D regimen taken for just 8 weeks without ribavirin led to sustained virological response in 98% of easier-to-treat non-cirrhotic patients with hepatitis C virus (HCV) genotype 1b, according to findings from the GARNET study, presented last week at the EASL special conference New Perspectives in Hepatitis C Virus Infection - The Roadmap for Cure in Paris.
Response-Guided DAA Triple Regimen May Cure Hepatitis C in as Little as 3 Weeks
- Details
- Category: Approved HCV Drugs
- Published on Monday, 24 October 2016 00:00
- Written by Liz Highleyman
Response-guided therapy using 3 direct-acting antivirals without ribavirin cured a majority of easier-to-treat genotype 1b hepatitis C patients in just 3 weeks, according to results from a small pilot study published in the October 2016 edition of The Lancet Gastroenterology & Hepatology.
Grazoprevir/Elbasvir Hepatitis C Treatment Works Wells for People Who Inject Drugs
- Details
- Category: Approved HCV Drugs
- Published on Wednesday, 10 August 2016 00:00
- Written by Liz Highleyman
Merck's grazoprevir/elbasvir hepatitis C regimen was well-tolerated and cured more than 90% of injection drug users receiving opioid substitution therapy, according to results from the C-EDGE CO-STAR study published in the August 9 online edition of Annals of Internal Medicine. The investigators reported that adherence was good even though many study participants continued to use illicit drugs.
Web Design and Development by